CL2015000744A1 - Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer. - Google Patents
Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer.Info
- Publication number
- CL2015000744A1 CL2015000744A1 CL2015000744A CL2015000744A CL2015000744A1 CL 2015000744 A1 CL2015000744 A1 CL 2015000744A1 CL 2015000744 A CL2015000744 A CL 2015000744A CL 2015000744 A CL2015000744 A CL 2015000744A CL 2015000744 A1 CL2015000744 A1 CL 2015000744A1
- Authority
- CL
- Chile
- Prior art keywords
- regorafenib
- combination
- cancer treatment
- acetylsalicylic acid
- treatment
- Prior art date
Links
- 239000002138 L01XE21 - Regorafenib Substances 0.000 title abstract 2
- 229960004836 regorafenib Drugs 0.000 title abstract 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 229960001138 acetylsalicylic acid Drugs 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000036571 hydration Effects 0.000 abstract 1
- 238000006703 hydration reaction Methods 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- ZOPOQLDXFHBOIH-UHFFFAOYSA-N regorafenib hydrate Chemical compound O.C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 ZOPOQLDXFHBOIH-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12185852 | 2012-09-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015000744A1 true CL2015000744A1 (es) | 2016-01-08 |
Family
ID=46963566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015000744A CL2015000744A1 (es) | 2012-09-25 | 2015-03-24 | Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer. |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10898500B2 (enExample) |
| EP (1) | EP2900269B1 (enExample) |
| JP (1) | JP6294888B2 (enExample) |
| KR (1) | KR102210575B1 (enExample) |
| CN (1) | CN104994876A (enExample) |
| AU (1) | AU2013322854B2 (enExample) |
| BR (1) | BR112015006686B1 (enExample) |
| CA (1) | CA2885688C (enExample) |
| CL (1) | CL2015000744A1 (enExample) |
| CY (1) | CY1120939T1 (enExample) |
| DK (1) | DK2900269T3 (enExample) |
| EA (1) | EA032023B1 (enExample) |
| ES (1) | ES2687985T3 (enExample) |
| HK (1) | HK1214169A1 (enExample) |
| HR (1) | HRP20181462T1 (enExample) |
| HU (1) | HUE039878T2 (enExample) |
| IL (1) | IL237690B (enExample) |
| LT (1) | LT2900269T (enExample) |
| MX (1) | MX357035B (enExample) |
| MY (1) | MY183969A (enExample) |
| NZ (1) | NZ705860A (enExample) |
| PH (1) | PH12015500587A1 (enExample) |
| PL (1) | PL2900269T3 (enExample) |
| PT (1) | PT2900269T (enExample) |
| RS (1) | RS57875B1 (enExample) |
| SG (2) | SG10201702356VA (enExample) |
| SI (1) | SI2900269T1 (enExample) |
| WO (1) | WO2014048881A1 (enExample) |
| ZA (1) | ZA201502840B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2861566T1 (sl) | 2012-06-13 | 2017-03-31 | F. Hoffmann-La Roche Ag | Novi diazaspirocikloalkan in azaspirocikloalkan |
| PL2900669T3 (pl) | 2012-09-25 | 2020-01-31 | F. Hoffmann-La Roche Ag | Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| AU2014356583B2 (en) | 2013-11-26 | 2019-02-28 | F. Hoffmann-La Roche Ag | New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl |
| CR20160418A (es) | 2014-03-26 | 2016-11-07 | Hoffmann La Roche | Nuevos compuestos biciclicos de 7 eslabones |
| MA50635A (fr) | 2014-03-26 | 2020-08-12 | Hoffmann La Roche | Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique |
| CN104829523B (zh) * | 2014-04-30 | 2017-10-31 | 药源药物化学（上海）有限公司 | 瑞戈非尼盐及其晶型、制备方法 |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| EP3344619B1 (en) | 2015-09-04 | 2020-10-28 | H. Hoffnabb-La Roche Ag | Phenoxymethyl derivatives |
| CN105267167A (zh) * | 2015-09-11 | 2016-01-27 | 江苏嘉逸医药有限公司 | 一种瑞戈非尼口服固体药物组合物的制备方法 |
| MA42918A (fr) | 2015-09-24 | 2018-08-01 | Hoffmann La Roche | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx |
| BR112018006080A2 (pt) | 2015-09-24 | 2018-10-09 | F. Hoffmann-La Roche Ag | novos compostos bicíclicos como inibidores de dupla ação de atx/ca |
| AU2016328437A1 (en) | 2015-09-24 | 2018-01-25 | F. Hoffmann-La Roche Ag | Bicyclic compounds as ATX inhibitors |
| WO2017050747A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual atx/ca inhibitors |
| LT3474858T (lt) * | 2016-06-28 | 2021-12-27 | Asamedic As | Dviejų komponentų kompozicija, apimanti acetilsalicilo rūgštį |
| EP3596060B1 (en) | 2017-03-16 | 2023-09-20 | F. Hoffmann-La Roche AG | New bicyclic compounds as atx inhibitors |
| RU2019132254A (ru) | 2017-03-16 | 2021-04-16 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca |
| PT3630112T (pt) * | 2017-06-02 | 2024-04-23 | Bayer Healthcare Llc | Combinação de regorafenib e nivolumab para tratamento de cancro |
| EP3501522A1 (en) | 2017-12-22 | 2019-06-26 | Asamedic AS | Compositions comprising acetylsalicylic acid and a phosphate salt |
| EP3501523A1 (en) | 2017-12-22 | 2019-06-26 | Asamedic AS | Two-component compositions comprising acetyl salicylic acid and a carbonate salt |
| KR20210156389A (ko) | 2020-06-17 | 2021-12-27 | 재단법인대구경북과학기술원 | 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001002014A1 (en) * | 1999-07-02 | 2001-01-11 | Hisamitsu Pharmaceutical Co., Inc. | Medicinal compositions for treating colorectal cancer |
| US20040121004A1 (en) * | 2002-12-20 | 2004-06-24 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
| PL1663978T3 (pl) | 2003-07-23 | 2008-04-30 | Bayer Healthcare Llc | Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów |
| JP2009514921A (ja) * | 2005-11-10 | 2009-04-09 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 糖尿病性神経障害を処置するためのジアリールウレア |
| AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| GB201002530D0 (en) * | 2010-02-15 | 2010-03-31 | Univ Wolverhampton The | Di-aspirin derivatives |
| AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
-
2013
- 2013-09-23 HR HRP20181462TT patent/HRP20181462T1/hr unknown
- 2013-09-23 HU HUE13770659A patent/HUE039878T2/hu unknown
- 2013-09-23 JP JP2015532437A patent/JP6294888B2/ja active Active
- 2013-09-23 WO PCT/EP2013/069735 patent/WO2014048881A1/en not_active Ceased
- 2013-09-23 DK DK13770659.4T patent/DK2900269T3/en active
- 2013-09-23 US US14/431,119 patent/US10898500B2/en active Active
- 2013-09-23 KR KR1020157010519A patent/KR102210575B1/ko active Active
- 2013-09-23 SI SI201331181T patent/SI2900269T1/sl unknown
- 2013-09-23 EP EP13770659.4A patent/EP2900269B1/en active Active
- 2013-09-23 ES ES13770659.4T patent/ES2687985T3/es active Active
- 2013-09-23 LT LTEP13770659.4T patent/LT2900269T/lt unknown
- 2013-09-23 CA CA2885688A patent/CA2885688C/en active Active
- 2013-09-23 PL PL13770659T patent/PL2900269T3/pl unknown
- 2013-09-23 HK HK16102326.3A patent/HK1214169A1/zh unknown
- 2013-09-23 AU AU2013322854A patent/AU2013322854B2/en active Active
- 2013-09-23 MY MYPI2015700911A patent/MY183969A/en unknown
- 2013-09-23 NZ NZ705860A patent/NZ705860A/en unknown
- 2013-09-23 RS RS20181015A patent/RS57875B1/sr unknown
- 2013-09-23 PT PT13770659T patent/PT2900269T/pt unknown
- 2013-09-23 CN CN201380050150.7A patent/CN104994876A/zh active Pending
- 2013-09-23 MX MX2015003728A patent/MX357035B/es active IP Right Grant
- 2013-09-23 SG SG10201702356VA patent/SG10201702356VA/en unknown
- 2013-09-23 EA EA201500365A patent/EA032023B1/ru not_active IP Right Cessation
- 2013-09-23 SG SG11201501963RA patent/SG11201501963RA/en unknown
- 2013-09-23 BR BR112015006686-0A patent/BR112015006686B1/pt active IP Right Grant
-
2015
- 2015-03-12 IL IL237690A patent/IL237690B/en active IP Right Grant
- 2015-03-17 PH PH12015500587A patent/PH12015500587A1/en unknown
- 2015-03-24 CL CL2015000744A patent/CL2015000744A1/es unknown
- 2015-04-24 ZA ZA2015/02840A patent/ZA201502840B/en unknown
-
2018
- 2018-09-20 CY CY181100976T patent/CY1120939T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021001425A (es) | Compuestos terapeuticos activos y sus usos. | |
| NI201600058A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| SV2016005137A (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| GT201500053A (es) | Composicion farmaceutica recubierta que contiene regorafenib | |
| CL2017002786A1 (es) | Referencia cruzada a solicitudes relacionadas | |
| SV2015005066A (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
| UY35590A (es) | Nuevos compuestos para el tratamiento del cáncer | |
| MX2019010422A (es) | Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la fosfoinositida 3-cinasa delta. | |
| CU20160052A7 (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| MX2016013457A (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| GEAP202114132A (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| CY1120939T1 (el) | Συνδυασμος ρεγοραφενιμπης και ακετυλοσαλικυλικου οξεος για τη θεραπευτικη αντιμετωπιση του ορθοκολικου καρκινου | |
| CL2015002608A1 (es) | Compuesto de amino-pirazol y usos medicinales relacionados. | |
| BR112016027041A2 (pt) | Combinações farmacêuticas para tratamento do câncer | |
| GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
| CL2016000009A1 (es) | Tratamiento de rosacea papulopustular con ivermectina. | |
| CU20160192A7 (es) | Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble | |
| DK3258938T3 (da) | Phenothiazinanaloger som mitokondrie terapeutiske midler | |
| CL2016001587A1 (es) | Derivado basado en 1,2-naftoquinona y método de preparación del mismo. | |
| SV2016005313A (es) | Derivados de carboxamida | |
| PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
| UY36292A (es) | Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios | |
| UY34786A (es) | Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo | |
| UY35823A (es) | Profármacos de antagonista de nmda |